Patients with Heart Failure Benefit from Ablation for Atrial Fibrillation

Patients with predominantly preserved ejection fraction experienced lower mortality and improved quality of life after ablation compared with drug therapy alone.

CABANA, one of the largest randomized controlled trials of ablation for atrial fibrillation (AF), did not demonstrate a benefit of ablation, compared with drug therapy alone, on the primary composite endpoint (death, disabling stroke, serious bleeding, or cardiac arrest) in an intention-to-treat analysis (partially industry-funded; NEJM JW Cardiol Jun 2019 and JAMA 2019; 321:1261). Now, researchers have reported results from a prespecified CABANA substudy of patients with heart failure (HF).

Of 2204 patients overall, 778 were characterized by the enrolling physician as having HF (New York Heart Association functional class II or greater) and were included in the substudy. Ejection fraction at baseline was known for only 73% of the patients; …

Reviewing Author

Mark S. Link, MD

Disclosures

Editorial BoardsCirculation; UpToDate

Mark S. Link, MD

Disclosures

Editorial BoardsCirculation; UpToDate

Patients with Heart Failure Benefit from Ablation for Atrial Fibrillation

Topics

Reviewing Author